^
Association details:
| Biomarker: | BRCA2 underexpression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug Class: | PARP inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Personalized Combination Therapies for Advanced Prostate Cancer with PARP Inhibitors
Published date:
05/28/2021
Excerpt:
We discovered that LNCaP cells expressed significantly lower levels of BRCA1/2 and ATM in comparison with VCaP and PC3, and PARPi treatment prompted a significant reduction in cell viability in LNCaP only.
